Browsing Health Sciences and Technology - Master's degree by Issue Date
Research and Teaching Output of the MIT Community
- Home
- →
- MIT Libraries
- →
- MIT Theses
- →
- Theses - Harvard-MIT Division of Health Sciences and Technology
- →
- Health Sciences and Technology - Master's degree
- →
- Browsing Health Sciences and Technology - Master's degree by Issue Date
JavaScript is disabled for your browser. Some features of this site may not work without it.
Browsing Health Sciences and Technology - Master's degree by Issue Date
-
(Massachusetts Institute of Technology, 2012)Hepatitis C (HCV) is the most common bloodborne infection in the United States. Although the incidence of HCV is declining, the burden of the disease is rising, driven by the increasing rates of end-stage liver disease and ...
-
(Massachusetts Institute of Technology, 2012)Targeted, especially stratified or biomarker-guided, therapies offer significant advantages over traditional oncology therapies in certain settings. Selecting patients most likely to respond to a drug increases the therapeutic ...
-
(Massachusetts Institute of Technology, 2012)Composite hydrogels find increasing use as biomaterials because the addition of a filler often improves on the material properties of the original matrix, or provides new optical, magnetic, conductive or bioactive ...
-
(Massachusetts Institute of Technology, 2012)Disruptive models of innovation are starting to appear in healthcare. In the US, for instance, retail medicine clinics are changing the way in which patients satisfy their basic medical needs. In Mexico, similar retail ...
-
(Massachusetts Institute of Technology, 2012)Over the past ten years there has been increasing public concern regarding the rising costs of pharmaceuticals. Drug expenditure is the fastest growing sector of healthcare costs in the United States. The structure of the ...
-
(Massachusetts Institute of Technology, 2012)The purpose of this research is to investigate potential strategic variables that executives at small to mid-sized biopharmaceutical companies should consider during the period of a drug launch. Bringing a product to market ...
-
(Massachusetts Institute of Technology, 2012)It has been estimated that 100 million plus individuals could perish if a virulent influenza pandemic were to occur. In wake of the 2009-10 H1N1 pandemic and in an era of economic austerity, however, industry lacks clear ...
-
(Massachusetts Institute of Technology, 2012)BACKGROUND: There is a high prevalence of disease marketing actions in the United States that are targeted towards patients with chronic illness. However, no study has assessed the direct effects of these marketing actions ...
-
(Massachusetts Institute of Technology, 2012)Successful translation of scientific discovery into new medicines is most successful with collaboration between academics - scientists and physicians - and industry. In recent years, there has been increasing concern at ...
-
(Massachusetts Institute of Technology, 2011)The aim of this thesis was to look at the impact of acquiring the CE marking approval on the outcome of early stage medical device companies, specifically its impact on strategic acquisition opportunities and on valuation. ...
-
(Massachusetts Institute of Technology, 2011)For this project, N-terminal and C-terminal peptide library fusions were designed,bconstructed, and screened in order to improve the repression achievable with a novel gene regulatory system. This system, based on the ...
-
(Massachusetts Institute of Technology, 2011)Interviews were conducted to establish a baseline for how orphan drug forecasting is currently undertaken by financial market and industry analysts with the intention of understanding the variables typically accounted for ...
-
(Massachusetts Institute of Technology, 2011)This thesis investigates the commercial viability of developing and commercializing targeted oncology drugs directed at a specific tumor mutation instead of all forms and mutations of a single target. While oncologic drugs ...
-
(Massachusetts Institute of Technology, 2011)The National Institutes of Health (NIH) has been the stalwart of research funding at universities and academic teaching hospitals. However, since the start of the last decade NIH funding has contracted in real terms. ...
-
(Massachusetts Institute of Technology, 2011)Understanding the true incidence and prevalence of a disease has tremendous value for the biopharmaceutical industry, particularly for orphan diseases that affect a minority of the population (in the US, the definition of ...
-
(Massachusetts Institute of Technology, 2011)The purpose of the research was to identify the clinical and commercial benefits of switching from intravenous (IV) to buccal delivery of antibiotics. then, the research continued to select 3-5 antibiotics that best met ...
-
(Massachusetts Institute of Technology, 2011)Access to the cerebral ventricle (e.g. ventriculostomy) is required to manage multiple life-threatening ailments. It can be done either in the operating room or at the bedside to relieve increased intracranial pressure or ...
-
(Massachusetts Institute of Technology, 2011)In the past decade, the practice of venture philanthropy, defined in this research as the provision of capital by a nonprofit entity to a for-profit company, has become an increasingly common asset allocation strategy for ...
-
(Massachusetts Institute of Technology, 2011)Innovation within the medical device industry had led to tremendous advances in the provision of care for patients worldwide. Continued progress in the treatment of disease will require effective processes for managing and ...
-
(Massachusetts Institute of Technology, 2011)Founders of new ventures in the medical technology (Medtech) industry require capital to establish, sustain, and grow their companies. Most founders must seek some form of external capital to meet these demands; in Medtech, ...
Browse
My Account
MIT-Mirage